Shih-Jer Hsu

Shih-Jer Hsu

Auto-generated profile, based on publicly available information

Shih-Jer Hsu

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
SHShang-Chin Huang
Shang-Chin Huang
TSTung-Hung Su
Tung-Hung Su
TTTai-Chung Tseng
Tai-Chung Tseng
SHShih-Jer Hsu
Shih-Jer Hsu
CHChun-Ming Hong
Chun-Ming Hong
JKJia-Horng Kao
Jia-Horng Kao

13 September 2021 in Liver International
Verified
Journal Article
Open access
PDF file
TSTung‐Hung Su
Tung‐Hung Su
SHShih‐Jer Hsu
Shih‐Jer Hsu
JKJia-Horng Kao
Jia-Horng Kao
Hepatocellular carcinoma (HCC) is prevalent worldwide with suboptimal therapeutic outcomes. The advancement of therapeutic options and the development of new systemic therapies expand the armamentarium to tackle HCC. Treatment options should be provided based on the hierarchy of efficacy in a multidisciplinary perspective, instead of the traditional stage‐guided scheme. In advanced HCC, lenvatinib has a comparable efficacy as sorafenib for the first‐line therapy of HCC; while regorafenib, cabozantinib, and ramucirumab have been approved as second‐line therapy after the failure of sorafenib. Immune checkpoint inhibitor therapy prolongs response rate and survival and enables long‐term cure. Atezolizumab plus bevacizumab is superior to sorafenib as the first‐line therapy for advanced HCC. Several emerging regimens by the combination of various systemic therapies are currently under clinical trials. Systemic therapy may be used in the neoadjuvant, adjuvant or even as initial therapy for intermediate‐stage HCC. The paradigm shift of HCC treatment will improve patient outcomes.

26 June 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SHShang-Chin Huang
Shang-Chin Huang
TSTung-Hung Su
Tung-Hung Su
TTTai-Chung Tseng
Tai-Chung Tseng
SLSih-Han Liao
Sih-Han Liao
SHShih-Jer Hsu
Shih-Jer Hsu
JKJia-Horng Kao
Jia-Horng Kao
INTRODUCTION: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing among the chronic hepatitis B (CHB) population. This study aimed to explore the impact of metabolic dysfunction (MD) on cirrhosis and cirrhotic complication risks in CHB. METHODS: Patients with CHB were consecutively recruited between 2006 and 2021. The presence of MD was based on the 5 cardiometabolic criteria specified in the MASLD definition. Patients were categorized into MD/non-MD groups based on these criteria. RESULTS: Eleven thousand five hundred two treatment-naive noncirrhotic patients with CHB were included with a median follow-up of 5.3 years. Patients in the MD group (n = 7,314) were older and had lower hepatitis B virus DNA levels than non-MD patients (n = 4,188). After adjustment for clinical and viral factors, MD patients had significantly higher risks of cirrhosis (adjusted hazard ratio [aHR]: 1.82, 95% confidence interval [CI]: 1.40–2.37, P < 0.001) and cirrhotic complications (aHR: 1.30 per MD, 95% CI: 1.03–1.63, P = 0.025) in a dose-dependent manner. Furthermore, new-onset diabetes mellitus during the follow-up aggravated the risk of cirrhotic complications (aHR: 2.87, 95% CI: 1.34–6.11, P = 0.006). Hepatic steatosis was associated with lower risks of cirrhosis (aHR: 0.57 within 5 years, 95% CI: 0.44–0.74, P < 0.001) and cirrhotic complications (aHR: 0.45, 95% CI 0.23–0.88, P = 0.020). Among individuals with hepatic steatosis, patients with MASLD exhibited a higher cirrhosis risk than non-MD patients. DISCUSSION: Concurrent and new-onset MDs increase the risks of cirrhosis and cirrhotic complications in patients with CHB, independent of hepatic steatosis. Proactively investigating metabolic comorbidities in CHB is critical to stratify the risk of liver disease progression.

3 May 2023 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
TSTung-Hung Su
Tung-Hung Su
SHShang-Chin Huang
Shang-Chin Huang
CCChi-Ling Chen
Chi-Ling Chen
SHShih-Jer Hsu
Shih-Jer Hsu
SLSih-Han Liao
Sih-Han Liao
JKJia-Horng Kao
Jia-Horng Kao
Surgical resection is a curative therapy for early-stage hepatocellular carcinoma (HCC); however, HCC recurrence is not uncommon. Identifying outcome predictors helps to manage the disease. Gamma-glutamyl transferase (GGT) may predict the development of HCC, but its role to predict the outcomes after surgical resection of HCC was unclear. This study aimed to investigate pre-operative GGT levels for outcome prediction in patients with hepatitis B virus (HBV)-related HCC. We conducted a retrospective cohort study to include patients with HBV-related HCC receiving surgical resection. Clinical information, HCC characteristics and usage of antiviral therapy were collected. A time-dependent Cox proportional hazard regression analysis were used to predict HCC recurrence and survival. A total of 699 consecutive patients with HBV-related HCC who received surgical resection with curative intent between 2004 and 2013 were included. After a median of 4.4 years, 266 (38%) patients had HCC recurrence. Pre-operative GGT positively correlated with cirrhosis, tumor burden and significantly increased in patients to develop HCC recurrence. Multivariable analysis demonstrated that pre-operative GGT ≥38 U/L increased 57% risk (hazard ratio [HR]: 1.57, 95% confidence interval [CI]: 1.20-2.06) of recurrent HCC after adjustment for confounding factors. Specifically, pre-operative GGT ≥38 U/L predicted early (<2 years) HCC recurrence (HR: 1.94, 95% CI: 1.30-2.89). Moreover, pre-operative GGT ≥38 U/L predicted all-cause mortality (HR: 1.73, 95% CI: 1.06-2.84) after surgery. Pre-operative GGT levels ≥38 U/L independently predict high risks of HCC recurrence and all-cause mortality in HBV-related HCC patients receiving surgical resection.

19 January 2023 in Liver Cancer
Verified
Journal Article
Open access
PDF file
CHChian-Tzu Huang
Chian-Tzu Huang
YCYu-Long Chu
Yu-Long Chu
TSTung-Hung Su
Tung-Hung Su
SHShang-Chin Huang
Shang-Chin Huang
TTTai-Chung Tseng
Tai-Chung Tseng
JKJia-Horng Kao
Jia-Horng Kao
Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC)-A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened, and those who received transarterial chemoembolization (TACE) or SR were consecutively included. The tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7–11), or high (>11). Multivariable Cox proportional hazard regression analysis was used for outcome prediction. Results: Overall, 474 patients who received SR (n = 247) and TACE (n = 227) were enrolled. Patients who underwent SR were significantly younger with better liver reserve. There were 76 (31%) and 129 (57%) deaths in the SR and TACE groups after a median follow-up of 3.9 and 2.1 years, respectively. The seven-eleven criteria could distinguish median overall survival (OS) among low (n = 149), intermediate (n = 203), and high (n = 122) tumor burden groups (7.7 vs. 6.9 vs. 2.8 years, respectively, p < 0.001). Patients receiving SR had a significantly higher median OS compared with TACE in those with intermediate (8.2 vs. 2.6 years, p < 0.001) and high (5.6 vs. 1.5 years, p = 0.001) tumor burden. After adjustment for age, sex, and liver reserve, SR was predictive for better OS in intermediate (adjusted hazard ratio [aHR]: 0.45, 95% confidence interval [CI]: 0.27–0.75) and high tumor burden groups (aHR: 0.54, 95% CI: 0.32–0.92). The survival benefit of SR especially confines to patients within 3 tumors. Conclusions: In patients with BCLC-A/B HCC beyond the Milan criteria with tumor burden beyond the up-to-7 criteria but within 3 tumors, SR has better OS than TACE and should be considered in resectable patients.

19 June 2025 in Liver Cancer
Verified
Journal Article
Open access
MWMing Shun Wu
Ming Shun Wu
WKWei-Yu Kao
Wei-Yu Kao
MCMing-Feng Chiang
Ming-Feng Chiang
PCPo-Heng Chuang
Po-Heng Chuang
SHShih-Jer Hsu
Shih-Jer Hsu
Chia-Chi WangChia-Chi Wang
Chia-Chi Wang
Metastatic liver tumors (MLTs) are the most common type of malignant liver tumors, primarily because the liver is a frequent target organ for metastasis. Metastatic cancer is generally considered a systemic disease, so the mainstay of treatment should be systemic therapies, including chemotherapy, targeted therapies, and immunotherapy. Currently, it is believed that a multimodal approach, combining local and systemic treatments, can improve tumor control and potentially prolong patient survival. Local treatments, in addition to surgery, include ablation therapy as one of the options. Ablation therapy has its limitations and advantages for local tumor control but can also be combined with other locoregional treatments such as surgical resection, transarterial embolization, and stereotactic body radiotherapy to manage appropriate subsets of patients. Ablation of hepatocellular carcinoma has been performed for many years. In recent years, the number of MLTs cases treated with ablation has been increasing. However, the characteristics of primary liver tumors and MLTs, as well as their responses to ablation therapy, are distinct. At present, there is no established international guideline specifically for the ablation treatment of MLTs. The consensus guidelines developed by the Taiwan Academy of Tumor Ablation (TATA) represent evidence-based medical statements. These guidelines are created and reviewed by an expert team including hepatologists, medical oncologists, radiation oncologists, and intervention radiologists through comprehensive medical literature searches, discussions, and voting. The process adheres to evidence-based standards, such as evaluating levels of evidence and grading recommendations. Furthermore, the guidelines are finalized through thorough discussions among all experts and by calculating voting consistency. In cases where clinical evidence is unclear or lacking, expert opinions are also incorporated. Additionally, the guidelines provide recommendations on the future development of ablation therapy for MLTs.